Welcome to Dr. Elliott Antman's AHA Emerging Science™ Series.

AHA is proud to introduce a new program to further science collaboration hosted by Dr. Elliot Antman: The AHA Emerging Science™ Series webinars are one hour professional quality webinars held three times per year. Dr. Antman will host each webinar, which will have two 30 minute blocks, consisting of presentations of original research from the following categories:

  • Late Breaking Clinical Trials
  • Clinical Trial Updates of previously presented LBCTs
  • Late Breaking Basic Science
  • Major Bench-to-Bedside Advances
  • Major Conference Proceedings
  • Major Guidelines/Policy Statements

The live webinar events will be viewable from a computer or mobile phone, both live and on-demand. Attendees can ask questions electronically during the live event or post event. 

Join us at the next event, or view for past events by visiting the Emerging Science Series page on Professional Heart Daily.

Latest Posts

Archive for December, 2012


The American Heart Association has the solution through the Emerging Science Series (ESS), our live webinars which provide a year-round venue for science presentation on a fast-tracked basis.  Submit by Thursday, January 3rd and if your science is accepted, you will be presenting via live webinar on Wednesday, February 27th.  AHA has the best science, the best education and the best opportunities for presentation. ESS science submission opens Wednesday, December 12th!

AHA's Emerging Science Series is accepting submissions from 
Dec 12-Jan 3, 2013, 
 5 p.m. CDT (UTC -06) 


Wed, December 12, 2012 Submission Opens
Thurs, January 3, 2013 Submission Closes
Wed, February 27, 2013 Webinar Event
Posted by Alyson PON Editor on Dec 10, 2012 2:15 PM CST

Most Recent Comments

I am intrigued by this exciting new AHA Emerging Science Series, and particularly interested to hear the discussion on the US subgroup analysis from PLATO.
I am very enthusiastic to hear more about tissue engineered vascular grafts. The science is quite provocative and the potential for clinical application is substantial!
As the Director of the Adult Invasive and Interventional Cardiology Program in Nassau, The Bahamas, I am excited to join the panel to discuss the implications of the PLATO US subgroup findings. Clearly dual antiplatelet therapy is at the center of the pharmacologic support for PCI and we need to understand the optimal regimen to protect our patients.
I am pleased to see a translational science presentation in this first webinar of the AHA Emerging Science Series. Using allogeneic fibroblasts to build a tissue engineered vascular graft is a creative approach to a common clinical problem. I look forward to learning more about how this was done and the results in the first in human experience.
The PLATO US substudy raises a number of important questions that will attract the attention of clinical trialists, interventional cardiologists, and vascular biologists. Should be an interesting discussion.